Avalon Investment & Advisory Abb Vie Inc. Transaction History

Avalon Investment & Advisory

$3.56 Billion
Q1 2023

A detailed history of Avalon Investment & Advisory transactions in Abb Vie Inc. stock. As of the latest transaction made, Avalon Investment & Advisory holds 248,957 shares of ABBV stock, worth $41.3 Million. This represents 1.11% of its overall portfolio holdings.

Number of Shares

248,957

Previous 254,190 2.06%

Holding current value

$41.3 Million

Previous $41.1 Million 3.42%

% of portfolio

1.11%

Previous 1.17%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $756,744 - $871,503	-5,233 Reduced 2.06%	248,957 $39.7 Million
Q4 2022 Feb 13, 2023	SELL	$138.31 - $165.87 $322,677 - $386,974	-2,333 Reduced 0.91%	254,190 $41.1 Million
Q3 2022 Nov 01, 2022	SELL	$134.21 - $153.93 $25.8 Million - $29.6 Million	-192,533 Reduced 42.88%	256,523 $34.4 Million
Q2 2022 Aug 10, 2022	SELL	$137.62 - $174.96 $19.5 Million - $24.8 Million	-141,854 Reduced 24.01%	449,056 $68.8 Million
Q1 2022 May 17, 2022	SELL	$131.98 - $163.75 $4.21 Million - $5.22 Million	-31,895 Reduced 5.12%	590,910 $95.8 Million

Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $9.61 Million - $12.2 Million	-89,477 Reduced 12.56%	622,805 $84.3 Million
Q3 2021 Nov 08, 2021	SELL	$106.4 - $120.78 $3.86 Million - $4.38 Million	-36,296 Reduced 4.85%	712,282 $76.8 Million
Q2 2021 Jul 29, 2021	SELL	$105.21 - $117.21 $7.79 Million - $8.68 Million	-74,058 Reduced 9.0%	748,578 $84.3 Million
Q1 2021 May 13, 2021	SELL	$102.3 - $112.62 $23.1 Million - $25.4 Million	-225,920 Reduced 21.55%	822,636 $89 Million
Q4 2020 Feb 08, 2021	BUY	$80.49 - $108.67 $1.01 Million - $1.36 Million	12,550 Added 1.21%	1,048,556 $112 Million
Q3 2020 Nov 04, 2020	SELL	$85.91 - $100.83 $1,804 - $2,117	-21 Reduced -0.0%	1,036,006 $90.7 Million
Q2 2020 Aug 07, 2020	BUY	$73.37 - $98.18 $6.39 Million - $8.55 Million	87,077 Added 9.18%	1,036,027 $102 Million
Q1 2020 May 05, 2020	BUY	$64.5 - $97.79 $27.3 Million - $41.3 Million	422,484 Added 80.25%	948,950 $72.3 Million
Q4 2019 Feb 14, 2020	BUY	$72.13 - $90.25 $2.73 Million - $3.41 Million	37,833 Added 7.74%	526,466 $46.6 Million
Q3 2019 Nov 14, 2019	BUY	$62.98 - $75.72 $16 Million - $19.2 Million	253,759 Added 108.04%	488,633 $37 Million
Q2 2019 Aug 14, 2019	SELL	$65.7 - $83.98 $114,646 - $146,545	-1,745 Reduced 0.74%	234,874 $17.1 Million
Q1 2019 Apr 24, 2019	SELL	$77.14 - $90.79 $13 Million - $15.3 Million	-168,540 Reduced 41.6%	236,619 $19.1 Million
Q4 2018 Feb 14, 2019	BUY	$77.85 - $96.01 $17.3 Million - $21.3 Million	221,819 Added 120.99%	405,159 $37.4 Million
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $16.3 Million - $18.1 Million	-183,331 Reduced 50.0%	183,340 $17.3 Million
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $1.19 Million - $1.41 Million	-13,257 Reduced 3.49%	366,671 $34 Million
Q1 2018 Jun 26, 2018	BUY	$92.01 - $123.21 $5.68 Million - $7.6 Million	61,700 Added 19.39%	379,928 $36 Million
Q1 2018 Jun 22, 2018	SELL	$92.01 - $123.21 $6.56 Million - $8.78 Million	-71,246 Reduced 18.29%	318,228 $30.8 Million
Q1 2018 May 15, 2018	BUY	$92.01 - $123.21 $6.56 Million - $8.78 Million	71,246 Added 22.39%	389,474 $36.9 Million
Q4 2017 Jun 22, 2018	SELL	$89.56 - $98.21 $1.46 Million - $1.6 Million	-16,340 Reduced 4.88%	318,228 $30.8 Million
Q4 2017 Feb 14, 2018	SELL	$89.56 - $98.21 $545,062 - $597,706	-6,086 Reduced 1.79%	334,568 $32.4 Million
Q3 2017 Nov 14, 2017	SELL	$69.85 - $89.22 $23.7 Million - $30.3 Million	-339,607 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	339,607	339,607 $24.6 Million

Others Institutions Holding ABBV

# of Institutions

3,652

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $293B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Avalon Investment & Advisory, based on Form 13F filings with the SEC.

News

Stay updated on Avalon Investment & Advisory with notifications on news.

Account

Avalon Investment & Advisory Abb Vie Inc. Transaction History